Anbio Biotechnology
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $8.6M | $8.2M | $6.7M | $23.5M |
| Cost of Revenue | $1.1M | $2.3M | $3.4M | $11.0M |
| Gross Profit | $7.5M | $5.9M | $3.4M | $12.6M |
| Gross Margin | 87.2% | 71.9% | 50.1% | 53.4% |
| Operating Expenses | ||||
| Research & Development | $201.3K | $454.2K | $134.7K | $200.0K |
| SG&A Expense | $1.6M | $3.4M | $1.3M | $2.2M |
| Operating Income | $5.8M | $2.0M | $2.0M | $10.2M |
| Operating Margin | 66.7% | 24.4% | 29.2% | 43.3% |
| Interest Expense | — | — | — | — |
| Pretax Income | $6.4M | $2.4M | $2.3M | $10.0M |
| Income Tax Expense | $0 | $0 | $0 | — |
| Net Income | $6.4M | $2.4M | $2.3M | $10.0M |
| Net Margin | 74.1% | 29.0% | 33.6% | 42.5% |
| EPS (Basic) | $0.15 | $0.06 | $0.11 | $0.47 |
| EPS (Diluted) | $0.15 | $0.06 | $0.11 | $0.47 |
| Shares Outstanding (Basic) | 43.7M | 42.3M | 21.4M | 21.4M |
| Shares Outstanding (Diluted) | 43.7M | 42.3M | 21.4M | 21.4M |
| Dividends Per Share | — | — | — | — |